FIELD: medicine.
SUBSTANCE: antibody under the invention is produced from Nicotiana benthamiana leaves by transient transfection of expression vectors. It represents immunoglobulin G and a tetramer consisting of two light and two heavy peptide chains and them larger supramolecular assemblies. The antibody is recovered both in the glycated, and in non-glycated form. The antibody is capable to bind selectively HER2/neu protein, to inhibit cancer cell proliferation. Using the antibody under the invention enables diagnosing HER2-positive breast cancer.
EFFECT: invention can be used for preparing drugs and diagnostic agent for breast cancer.
8 dwg, 4 ex
| Title | Year | Author | Number |
|---|---|---|---|
| METHOD OF HER2/neu ONCOGENE ANTIBODY SUPERPRODUCTION IN PLANT | 2007 |
|
RU2370280C2 |
| METHOD OF OBTAINING THE ANTIBODY, WHICH SPECIFICALLY BINDS THE DOMAIN OF THE HER2/NEU EXCELLULAR PART OF THE HER2/NEU ONCOPROTEIN, IN THE PLANT, THE ANTIBODY, WHICH IS OBTAINED BY MEANS OF THIS METHOD AND ITS APPLICATION | 2016 |
|
RU2648161C2 |
| ANTI-HER2 ANTIBODY AND CONJUGATE THEREOF | 2014 |
|
RU2656161C1 |
| MUTANT FULLY HUMANISED ANTIBODY AGAINST HER2 AND ENCODING GENE AND THEIR APPLICATION | 2015 |
|
RU2639531C1 |
| MAT40 ANTIBODY BINDING WITH DOMAIN I OF EXTRACELLULAR PART OF EPIDERMAL HER2/CD340 GROWTH FACTOR RECEPTOR, AND ITS APPLICATION FOR CANCER TREATMENT | 2015 |
|
RU2640259C2 |
| TARGETED/IMMUNOMODULATING FUSION PROTEINS AND METHODS FOR THEIR OBTAINING | 2013 |
|
RU2636342C2 |
| IDENTIFICATION OF PATIENTS IN NEED OF COMBINED THERAPY WITH PD-L1 INHIBITOR | 2013 |
|
RU2692773C2 |
| MEANS OF IDENTIFICATION OF TUMOURS, ACQUISITIVE TO TREATMENT BY ANTIBODIES AGAINST ErbB2 | 2003 |
|
RU2338751C2 |
| MODIFIED ANTIBODIES LINKED WITH MOTIF INCLUDING CYSTEINE ??RESIDUE, CONJUGATES OF SAID MODIFIED ANTIBODY WITH DRUG SUBSTANCE AND METHODS OF PRODUCING SAME | 2013 |
|
RU2582259C2 |
| DIAGNOSTIC TECHNIQUE FOR BREAST CANCER WITH HER2/NEU RECEPTOR EXPRESSION ON A TUMOR CELL MEMBRANE | 2018 |
|
RU2701356C1 |
